Welcome to our dedicated page for DiaMedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DiaMedica Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke. Form 8-K reports cover operating and financial results, business updates, clinical and regulatory disclosures, material agreements and executive leadership changes.
The company’s proxy materials describe shareholder meeting matters, board governance, executive compensation and equity award information. Other filings address capital-structure activity, including at-the-market common share sales arrangements, as well as Regulation FD disclosures and risk-language tied to DM199 development and regulatory interactions.
DiaMedica Therapeutics Inc. reported that its CFO and Secretary, Kellen Scott, received a grant of stock options classified as a derivative security. The award covers 162,000 stock options, each giving the right to buy one voting common share at an exercise price of $5.84 per share.
The options were granted as compensation, not as an open-market purchase, and are held directly. They are scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments, and they expire on June 1, 2036.
DiaMedica Therapeutics Inc. reported that its Chief Medical Officer, Julie Krop, received a new stock option grant. The award covers 67,500 stock options with an exercise price of $5.84 per share and expires on June 1, 2036.
The options relate to 67,500 voting common shares and were granted at no upfront cost as a compensation award. According to the vesting terms, 25% of the options are scheduled to vest on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments thereafter.
DiaMedica Therapeutics Inc. reported results from its 2026 Annual General Meeting of Shareholders. All seven incumbent directors were re-elected, with most nominees receiving over 10 million votes in favor. Shareholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026.
On an advisory basis, shareholders approved the company’s executive compensation, with 9,928,381 votes for and 271,093 against. They also approved an amendment to the Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,500,000 shares.
DiaMedica Therapeutics reported a net loss of $10.0 million for the quarter ended March 31, 2026, compared with $7.7 million a year earlier, driven mainly by higher research and development spending.
R&D expenses rose to $8.0 million from $5.7 million as the company expanded its Phase 2/3 ReMEDy2 trial in acute ischemic stroke and advanced DM199 into preeclampsia and fetal growth restriction. General and administrative costs were stable at $2.5 million.
The company had $51.3 million in combined cash, cash equivalents and marketable securities, working capital of $46.6 million and shareholders’ equity of $47.2 million. Management believes these resources will fund planned operations for at least the next 12 months while it continues DM199 clinical development, despite slower-than-expected enrollment in ReMEDy2 and an interim analysis currently estimated for the fourth quarter of 2026.
DiaMedica Therapeutics reported first quarter 2026 results with a higher net loss as it advanced its clinical programs in preeclampsia, fetal growth restriction and acute ischemic stroke.
Net loss was $10,042 thousand compared to $7,707 thousand a year earlier, driven mainly by increased research and development spending of $7,987 thousand versus $5,656 thousand. General and administrative expenses were stable at $2,495 thousand compared to $2,488 thousand.
Basic and diluted net loss per share was $0.19 on 53,793,490 weighted average shares, compared to $0.18 on 42,843,938 shares. As of March 31, 2026, cash and cash equivalents were $4,868 thousand and marketable securities were $46,463 thousand. Net cash used in operating activities was $9,082 thousand for the quarter.
DiaMedica Therapeutics Inc. is asking shareholders at its May 20, 2026 annual meeting to elect seven directors, ratify Baker Tilly US, LLP as auditor, approve executive pay on an advisory basis, and expand its 2019 Omnibus Incentive Plan.
The plan amendment would add 3,500,000 shares for equity awards, bringing the plan’s total authorization to 10,500,000 shares and extending its term by ten years. As of March 23, 2026, DiaMedica had 53,805,628 common shares outstanding and disclosed a three-year average equity award burn rate of about 5.3%.
DiaMedica Therapeutics Inc. reported full-year 2025 results showing a larger operating loss as it increased investment in its clinical pipeline while maintaining a strong cash position. Total operating expenses rose to 34,397 (in thousands) from 26,681 (in thousands), driven by higher research and development and general and administrative spending.
The company recorded a net loss of 32,766 (in thousands) for 2025 compared with 24,444 (in thousands) in 2024. As of December 31, 2025, cash and cash equivalents were 15,647 (in thousands) and marketable securities were 44,243 (in thousands), supported by 43,282 (in thousands) of net proceeds from common share issuances. Management expects this cash runway to fund operations through the second half of 2027 while advancing its DM199 programs in preeclampsia, fetal growth restriction, and acute ischemic stroke, including the ongoing ReMEDy2 Phase 2/3 trial and planned Phase 2 studies in early-onset preeclampsia.
DiaMedica Therapeutics Inc. outlines its strategy as a clinical-stage biopharmaceutical company developing DM199, a recombinant human tissue kallikrein-1, for preeclampsia, fetal growth restriction and acute ischemic stroke. DM199 has U.S. Fast Track designation for stroke and is supported by extensive Asian experience with urinary and porcine KLK1 analogs.
The company highlights interim Phase 2 preeclampsia data from South Africa showing statistically significant blood pressure reductions, improved uterine artery blood flow and no placental transfer signals. In stroke, the global Phase 2/3 ReMEDy2 trial treats patients within 24 hours of symptom onset, targeting the majority of patients who are ineligible for tPA/TNK or mechanical thrombectomy. DiaMedica also describes a broad patent estate around DM199 and DM300, long potential exclusivity, and reliance on Catalent for GMP manufacturing.
DiaMedica Therapeutics investor Leon G. Cooperman reports beneficial ownership of 3,450,000 voting common shares, representing 6.6% of the company’s outstanding shares based on 52,077,439 shares outstanding as of November 10, 2025. The stake consists of 2,450,000 shares held directly by Mr. Cooperman and 1,000,000 shares held by The Leon and Toby Cooperman Foundation, a charitable trust where he is a trustee. He reports sole voting and dispositive power over all 3,450,000 shares and certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of DiaMedica.